Table 2 Hematologic and cytogenetic... | American Society of Hematology

Table 2

Hematologic and cytogenetic response to nilotinib in accelerated-phase CML

Parameter	N = 119 patients, no. (%)*
HR
Overall HR (CHR+MR/NEL+RTC)	56 (47)
CHR	31 (26)
MR/NEL	11 (9)
RTC	14 (12)
No response (includes stable disease)	11 (9)
Progression	13 (11)
Death	3 (3)
Not assessable	36 (30)†
Cytogenetic response
MCyR (CCyR+PCyR)	35 (29)
CCyR	19 (16)
PCyR	16 (13)
Minor cytogenetic response	16 (13)
Minimal cytogenetic response	28 (24)
No response/not assessable	19 (16)

Parameter	N = 119 patients, no. (%)*
HR
Overall HR (CHR+MR/NEL+RTC)	56 (47)
CHR	31 (26)
MR/NEL	11 (9)
RTC	14 (12)
No response (includes stable disease)	11 (9)
Progression	13 (11)
Death	3 (3)
Not assessable	36 (30)†
Cytogenetic response
MCyR (CCyR+PCyR)	35 (29)
CCyR	19 (16)
PCyR	16 (13)
Minor cytogenetic response	16 (13)
Minimal cytogenetic response	28 (24)
No response/not assessable	19 (16)

Patients with at least 6 months of follow-up unless discontinued the study early (″Methods″).

33% of patients had less than 2 postbaseline efficacy assessments for HR (in absence of progressive disease or death).